Cadrenal Therapeutics, Inc. (CVKD) stock
CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.88+0.48 (+34.29%)
Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%
Cadrenal Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Cadrenal Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.83M, down 44.1% year over year. For fiscal 2025 it was $4.10M, down 2.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.10M | -2.5% |
| FY2024 | Dec 31, 2024 | $4.21M | +3.0% |
| FY2023 | Dec 31, 2023 | $4.08M | +1940.7% |
| FY2008 | Mar 31, 2008 | $200.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $705.15K | -34.6% |
| Q1 FY2026 | Mar 31, 2026 | $771.51K | -53.7% |
| Q4 FY2025 | Dec 31, 2025 | $666.32K | -56.7% |
| Q3 FY2025 | Sep 30, 2025 | $688.47K | -12.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.08M | -14.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.67M | +165.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.54M | +325.8% |
| Q3 FY2024 | Sep 30, 2024 | $784.65K | -75.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.25M | – |
| Q1 FY2024 | Mar 31, 2024 | $629.03K | – |
| Q4 FY2023 | Dec 31, 2023 | $361.13K | – |
| Q1 FY2023 | Mar 31, 2023 | $3.24M | – |
See a number that looks wrong?